Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. GLMD
stocks logo

GLMD

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Valuation Metrics

The current forward P/E ratio for Galmed Pharmaceuticals Ltd (GLMD.O) is -0.93, compared to its 5-year average forward P/E of -1.22. For a more detailed relative valuation and DCF analysis to assess Galmed Pharmaceuticals Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.22
Current PE
-0.93
Overvalued PE
-0.20
Undervalued PE
-2.25

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.05
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.90
Undervalued EV/EBITDA
-0.79

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

GLMD News & Events

Events Timeline

(ET)
2025-12-04
08:40:00
Galmed Secures New Use Patent for Aramchol
select
2025-12-01 (ET)
2025-12-01
08:40:00
Galmed Pharmaceuticals CEO Letter: Strong Cash Position and Strategic Expansion
select
2025-11-26 (ET)
2025-11-26
08:32:18
Galmed announces Q3 earnings per share of 33 cents, compared to a loss of $2.31 in the same period last year.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
03:22 AMGlobenewswire
PinnedGalimedix Reports Excellent Phase 1 Results for GAL-101 with No Adverse Events
  • Clinical Trial Success: Galimedix presented Phase 1 study results for GAL-101 at CTAD 2025, involving approximately 100 healthy volunteers, demonstrating excellent safety and tolerability with no dose-limiting adverse events, indicating the drug's potential in Alzheimer's treatment.
  • Drug Penetration Capability: GAL-101 confirmed effective blood-brain barrier penetration with lumbar CSF concentrations after multiple doses, supporting a once-daily dosing regimen for future trials, which may enhance patient adherence to treatment.
  • Future Research Planning: Following positive Phase 1 results, Galimedix is planning a Phase 2 proof-of-concept study in Alzheimer's disease, expected to include cognitive functional endpoints and biomarkers to capture early signs of cognitive improvement.
  • Technological Innovation: As a small molecule targeting misfolded amyloid beta monomers to prevent toxic aggregate formation, GAL-101 shows broad application prospects in treating Alzheimer's disease, dry age-related macular degeneration, and glaucoma.
[object Object]
Preview
3.5
12-04PRnewswire
Galmed Secures New Patent for Aramchol, Extending Protection to 2042
  • Patent Protection Extension: Galmed Pharmaceuticals has secured a new use patent for Aramchol in South Korea, extending global patent protection to 2042, thereby reinforcing its market leadership in the non-alcoholic steatohepatitis (NASH) sector.
  • Clinical Readiness: As a first-in-class candidate ready for Phase 3 trials, Aramchol has demonstrated significant fibrosis improvement in clinical studies, indicating its potential in treating complex diseases.
  • Combination Therapy Outlook: The new patent covers the combination therapy of Aramchol and Rezdiffra, aligning with the industry's shift towards combination therapies, which is expected to drive the initiation of clinical studies and meet market demand for effective treatments.
  • Safety Advantage: Aramchol's excellent safety and tolerability make it an ideal candidate for combination with other MASH drugs, potentially enhancing its market acceptance and driving sales growth.
[object Object]
Preview
9.5
12-01PRnewswire
Galmed Pharmaceuticals Reports $19.2M Cash Position, Advancing Clinical Development
  • Strong Cash Position: Galmed Pharmaceuticals ended Q3 2025 with approximately $19.2 million in cash and virtually no debt, ensuring operational flexibility while increasing R&D investments to support expanded clinical studies, thereby providing a solid foundation for executing both short and long-term development plans.
  • Significant Clinical Advancements: The recent Phase 3 results for Aramchol in MASH and liver fibrosis showed that 65% and 100% of patients experienced fibrosis improvement at week 48, indicating substantial commercial potential in a market projected to reach $16 billion by 2033 due to high unmet needs.
  • New Drug Combination Development: Galmed is developing a new sublingual formulation of Aramchol for combination therapy with other metabolic agents, which, if successful, will allow for the prompt initiation of a Phase 2 clinical study in MASH, significantly expanding its market opportunities in liver disease.
  • Oncology Expansion: Early findings from combination studies of Aramchol with Stivarga indicate enhanced efficacy against various GI cancers, with plans to initiate clinical trials for metastatic colorectal cancer and hepatocellular carcinoma in early 2026, further solidifying the company's strategic positioning in oncology.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Galmed Pharmaceuticals Ltd (GLMD) stock price today?

The current price of GLMD is 1.13 USD — it has increased 5.61 % in the last trading day.

arrow icon

What is Galmed Pharmaceuticals Ltd (GLMD)'s business?

Galmed Pharmaceuticals Ltd. is an Israel-based biopharmaceutical company dedicated to the development of therapeutics for the treatment of liver diseases. The Company is focused its research and development efforts on addressing unmet medical needs in the field of liver health. The Company's flagship product is Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule. Aramchol is aimed to be effective in the treatment of non-alcoholic steatohepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The Company's drug aims to be efficient treatment of NASH, a chronic liver disease characterized by fat accumulation, inflammation, and fibrosis, which can lead to cirrhosis and liver cancer if left untreated.

arrow icon

What is the price predicton of GLMD Stock?

Wall Street analysts forecast GLMD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLMD is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Galmed Pharmaceuticals Ltd (GLMD)'s revenue for the last quarter?

Galmed Pharmaceuticals Ltd revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Galmed Pharmaceuticals Ltd (GLMD)'s earnings per share (EPS) for the last quarter?

Galmed Pharmaceuticals Ltd. EPS for the last quarter amounts to -0.63 USD, decreased -70.42 % YoY.

arrow icon

What changes have occurred in the market's expectations for Galmed Pharmaceuticals Ltd (GLMD)'s fundamentals?

The market is revising No Change the revenue expectations for Galmed Pharmaceuticals Ltd. (GLMD) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -16.91%.
arrow icon

How many employees does Galmed Pharmaceuticals Ltd (GLMD). have?

Galmed Pharmaceuticals Ltd (GLMD) has 3 emplpoyees as of December 05 2025.

arrow icon

What is Galmed Pharmaceuticals Ltd (GLMD) market cap?

Today GLMD has the market capitalization of 6.19M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free